小方制药(603207.SH)：前三季度净利润1.7亿元，同比增长5.09%

Core Viewpoint - Xiaofang Pharmaceutical (603207.SH) reported a year-on-year revenue increase of 8.17% for the first three quarters of 2025, reaching 397 million yuan, along with a net profit attributable to shareholders of 170 million yuan, reflecting a growth of 5.09% [1] Financial Performance - Total operating revenue for the first three quarters of 2025 was 397 million yuan, representing an 8.17% increase year-on-year [1] - Net profit attributable to the parent company's shareholders was 170 million yuan, showing a year-on-year growth of 5.09% [1] - Basic earnings per share stood at 1.06 yuan [1]